The U.S. Supreme Court has voted unanimously that human genes acquired through an isolation process do not constitute property that may be patent protected. However, the decision does not extend to artificially produced nor artificially altered human genes unless the result already exists in nature. Per the article:

 

The central question for the justices in the case, Association for Molecular Pathology v. Myriad Genetics, No. 12-398, was whether isolated genes are “products of nature” that may not be patented or “human-made inventions” eligible for patent protection....The decision hewed closely to the position of the Obama administration, which had argued that isolated DNA could not be patented, but that complementary DNA, or cDNA, which is an artificial construct, could....But manipulating a gene to create something not found in nature, Justice Thomas added, is an invention eligible for patent protection.

 

http://www.nytimes.com/2013/06/14/us/supreme-court-rules-human-gene...

Tags: Copyrights, DNA, Genetics, Jubinsky, Patents

Views: 201

Replies to This Discussion

Yea!  SCOTUS finally got their stuff together... once.  Patenting appears to be the new methodology for corporations to stockpile potential gold mine ownership.  Anyone wondering how many other, heretofore unknown processes, inventions and medical breakthroughs have been silently patented and tucked away for future use?  A cure for cancer, perhaps? A bio-degradable product that will one day replace gas and oil?

My intent is not to cry wolf, rather to draw ever more scrutiny into the business plans of corporations in the global economy leadership group.  The first step, obviously, would be to identify them; or, are they similar to the internet - pervasive without a face source?

Myriad is the face of this particular decision, but who's behind them?

RSS

Support Atheist Nexus

Donate Today

Donate

 

Help Nexus When You Buy From Amazon

Amazon

AJY

 

© 2014   Atheist Nexus. All rights reserved. Admin: Richard Haynes.

Badges  |  Report an Issue  |  Terms of Service